Immunotherapy developer Zenas BioPharma (ZBIO.US) applies for listing in the US, planning to raise $100 million.

Immune therapy developer Zenas BioPharma submitted its initial public offering (IPO) application to the US Securities and Exchange Commission (SEC) on Thursday, planning to raise $100 million. The company plans to list on Nasdaq with the stock code "ZBIO". According to information, Zenas BioPharma is a company focused on developing immune therapies for patients, with extensive clinical expertise in designing and executing early to late-stage clinical projects. The company's main candidate drug, obexelimab, is a dual-function monoclonal antibody designed to target CD19 and FcRIIb to inhibit the activity of B cells, plasma cells, and CD19-expressing plasma cells. Currently, the drug is being evaluated in clinical trials for multiple indications. Data shows that the company had revenue of $50 million for the 12 months ending June 30, 2024.